NASDAQ:SLDB - Solid Biosciences Stock Price, News, & Analysis

$5.01
+0.02 (+0.40 %)
(As of 06/18/2019 04:01 AM ET)
Today's Range
$4.90
Now: $5.01
$5.09
50-Day Range
$4.86
MA: $6.68
$10.1050
52-Week Range
$4.71
Now: $5.01
$54.84
Volume150,697 shs
Average Volume769,987 shs
Market Capitalization$177.38 million
P/E RatioN/A
Dividend YieldN/A
Beta2.31
Solid Biosciences Inc, a life science company, engages in identifying and developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, an adeno-associated viral vector-mediated gene transfer, which is in a Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SLDB
CUSIPN/A
Phone617-337-4680

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.53 per share

Profitability

Net Income$-74,800,000.00

Miscellaneous

Employees111
Market Cap$177.38 million
Next Earnings Date8/9/2019 (Estimated)
OptionableOptionable

Receive SLDB News and Ratings via Email

Sign-up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter.

Solid Biosciences (NASDAQ:SLDB) Frequently Asked Questions

What is Solid Biosciences' stock symbol?

Solid Biosciences trades on the NASDAQ under the ticker symbol "SLDB."

How were Solid Biosciences' earnings last quarter?

Solid Biosciences Inc (NASDAQ:SLDB) posted its earnings results on Monday, May, 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.22. View Solid Biosciences' Earnings History.

When is Solid Biosciences' next earnings date?

Solid Biosciences is scheduled to release their next quarterly earnings announcement on Friday, August 9th 2019. View Earnings Estimates for Solid Biosciences.

What price target have analysts set for SLDB?

8 brokers have issued 1-year target prices for Solid Biosciences' stock. Their forecasts range from $4.00 to $57.00. On average, they anticipate Solid Biosciences' share price to reach $21.75 in the next twelve months. This suggests a possible upside of 334.1% from the stock's current price. View Analyst Price Targets for Solid Biosciences.

What is the consensus analysts' recommendation for Solid Biosciences?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Solid Biosciences in the last year. There are currently 2 sell ratings, 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Solid Biosciences.

What are Wall Street analysts saying about Solid Biosciences stock?

Here are some recent quotes from research analysts about Solid Biosciences stock:
  • 1. According to Zacks Investment Research, "Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001, a gene transfer candidate which is in Phase I/II clinical trial to restore functional dystrophin protein expression in patients' muscles. Solid Biosciences LLC is headquartered in Cambridge, Massachusetts. " (6/15/2019)
  • 2. Chardan Capital analysts commented, "We thus downgrade SLDB from Buy to Neutral. This is not the 1st time Solid has seen unusual side effects in the development of SGT-001. Solid announced the FDA placed a clinical hold on the IGNITE DMD trial after the 1st patient experienced decreased platelet counts, reduced red blood cell counts, and evidence of complement activation. The hold was subsequently lifted, and the company announced changes to the trial protocol, including 1) the use of IV glucocorticoids in the initial weeks after treatment; 2) additional monitoring after dosing; and, 3) the option to collect a biopsy at 45 days post-treatment." (5/14/2019)

Has Solid Biosciences been receiving favorable news coverage?

News coverage about SLDB stock has trended very positive this week, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Solid Biosciences earned a media sentiment score of 3.3 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Solid Biosciences.

Are investors shorting Solid Biosciences?

Solid Biosciences saw a drop in short interest in May. As of May 15th, there was short interest totalling 2,904,400 shares, a drop of 18.1% from the April 15th total of 3,545,900 shares. Based on an average daily trading volume, of 715,800 shares, the short-interest ratio is presently 4.1 days. Approximately 12.6% of the company's stock are sold short. View Solid Biosciences' Current Options Chain.

Who are some of Solid Biosciences' key competitors?

What other stocks do shareholders of Solid Biosciences own?

Who are Solid Biosciences' key executives?

Solid Biosciences' management team includes the folowing people:
  • Dr. Andrey Juan Zarur, Co-Founder & Chairman of Directors (Age 48)
  • Mr. Ilan Ganot, Co-founder, Pres, CEO & Director (Age 45)
  • Mr. Pedro Alvaro Amorrortu, Chief Operating Officer (Age 47)
  • Dr. Carl Ashley Morris, Chief Scientific Officer (Age 49)
  • Dr. Andrey Zarur Ph.D., Co-Founder & Chairman of Directors (Age 48)

When did Solid Biosciences IPO?

(SLDB) raised $130 million in an IPO on Friday, January 26th 2018. The company issued 7,000,000 shares at a price of $18.00-$19.00 per share. J.P. Morgan, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO and Nomura and Chardan were co-managers.

Who are Solid Biosciences' major shareholders?

Solid Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Spark Investment Management LLC (0.90%), Emory University (0.84%), Marshall Wace LLP (0.20%), Matisse Capital (0.19%), Acadian Asset Management LLC (0.10%) and Virtu Financial LLC (0.06%). Company insiders that own Solid Biosciences stock include Boxer Capital, Llc, Ilan Ganot, Joel Solomon Zev Schneider, Jorge Armando Quiroz, Juan Andrey Zarur, Life Sciences Maste Perceptive, Matthew Bennett Arnold and Pedro Alvaro Amorrortu. View Institutional Ownership Trends for Solid Biosciences.

Which institutional investors are buying Solid Biosciences stock?

SLDB stock was purchased by a variety of institutional investors in the last quarter, including Emory University, Spark Investment Management LLC, Matisse Capital, Marshall Wace LLP, Acadian Asset Management LLC, Virtu Financial LLC and NumerixS Investment Technologies Inc. View Insider Buying and Selling for Solid Biosciences.

How do I buy shares of Solid Biosciences?

Shares of SLDB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Solid Biosciences' stock price today?

One share of SLDB stock can currently be purchased for approximately $5.01.

How big of a company is Solid Biosciences?

Solid Biosciences has a market capitalization of $177.38 million. The company earns $-74,800,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Solid Biosciences employs 111 workers across the globe.View Additional Information About Solid Biosciences.

What is Solid Biosciences' official website?

The official website for Solid Biosciences is http://www.solidbio.com/.

How can I contact Solid Biosciences?

Solid Biosciences' mailing address is 141 PORTLAND STREET FIFTH FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-337-4680.


MarketBeat Community Rating for Solid Biosciences (NASDAQ SLDB)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  148 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  280
MarketBeat's community ratings are surveys of what our community members think about Solid Biosciences and other stocks. Vote "Outperform" if you believe SLDB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLDB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel